Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Rodriguez OC, Lai EW, Vissapragada S, Cromelin C, Avetian M, Salinas P, Ramos H, Kallakury B, Casimiro M, Lisanti MP, Tanowitz HB, Pacak K, Glazer RI, Avantaggiati M, Albanese C.

Am J Pathol. 2009 Jun;174(6):2051-60. doi: 10.2353/ajpath.2009.080859. Epub 2009 May 14.

2.

Pten inactivation and the emergence of androgen-independent prostate cancer.

Shen MM, Abate-Shen C.

Cancer Res. 2007 Jul 15;67(14):6535-8. Review.

3.

NOTCH and PTEN in prostate cancer.

Bertrand FE, McCubrey JA, Angus CW, Nutter JM, Sigounas G.

Adv Biol Regul. 2014 Sep;56:51-65. doi: 10.1016/j.jbior.2014.05.002. Epub 2014 May 22. Review.

PMID:
24933481
4.

Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Muniyan S, Ingersoll MA, Batra SK, Lin MF.

Biochim Biophys Acta. 2014 Aug;1846(1):88-98. doi: 10.1016/j.bbcan.2014.04.006. Epub 2014 Apr 18. Review.

5.

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Irshad S, Abate-Shen C.

Cancer Metastasis Rev. 2013 Jun;32(1-2):109-22. doi: 10.1007/s10555-012-9409-1. Review.

Supplemental Content

Support Center